Venn Life Sciences last month announced that it would be acquiring a complementary early stage Contract Research Organisation, Netherlands Based Kinesis Pharma, subject to a general meeting called for 9th October. The company simultaneously announced a £3.57m placing at 22p. Venn has already established itself as a quality provider of clinical research services, and is carving a niche as a provider to the well-funded biotechnology industry, as demonstrated by the larger size of recent b
05 Oct 2015
Moving up the value chain
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Moving up the value chain
hVIVO plc (HVO:LON) | 26.5 -0.1 (-2.0%) | Mkt Cap: 180.3m
- Published:
05 Oct 2015 -
Author:
Derren Nathan -
Pages:
20
Venn Life Sciences last month announced that it would be acquiring a complementary early stage Contract Research Organisation, Netherlands Based Kinesis Pharma, subject to a general meeting called for 9th October. The company simultaneously announced a £3.57m placing at 22p. Venn has already established itself as a quality provider of clinical research services, and is carving a niche as a provider to the well-funded biotechnology industry, as demonstrated by the larger size of recent b